BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23991643)

  • 1. Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness.
    Worhunsky DJ; Krampitz GW; Poullos PD; Visser BC; Kunz PL; Fisher GA; Norton JA; Poultsides GA
    HPB (Oxford); 2014 Apr; 16(4):304-11. PubMed ID: 23991643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis.
    Poultsides GA; Huang LC; Chen Y; Visser BC; Pai RK; Jeffrey RB; Park WG; Chen AM; Kunz PL; Fisher GA; Norton JA
    Ann Surg Oncol; 2012 Jul; 19(7):2295-303. PubMed ID: 22396008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems.
    Benetatos N; Hodson J; Marudanayagam R; Sutcliffe RP; Isaac JR; Ayuk J; Shah T; Roberts KJ
    Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):169-175. PubMed ID: 29576279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of multidetector CT features in predicting overall survival outcomes in patients with pancreatic neuroendocrine tumors.
    Yang B; Chen HY; Zhang XY; Pan Y; Lu YF; Yu RS
    Eur J Radiol; 2020 Mar; 124():108847. PubMed ID: 31991300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of Pancreatic Neuroendocrine Tumor Grade Based on CT Features and Texture Analysis.
    Canellas R; Burk KS; Parakh A; Sahani DV
    AJR Am J Roentgenol; 2018 Feb; 210(2):341-346. PubMed ID: 29140113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shape and Enhancement Characteristics of Pancreatic Neuroendocrine Tumor on Preoperative Contrast-enhanced Computed Tomography May be Prognostic Indicators.
    Okabe H; Hashimoto D; Chikamoto A; Yoshida M; Taki K; Arima K; Imai K; Tamura Y; Ikeda O; Ishiko T; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Yamashita YI; Yoshizumi T; Beppu T; Yamashita Y; Baba H; Maehara Y
    Ann Surg Oncol; 2017 May; 24(5):1399-1405. PubMed ID: 27896509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors.
    Titan AL; Norton JA; Fisher AT; Foster DS; Harris EJ; Worhunsky DJ; Worth PJ; Dua MM; Visser BC; Poultsides GA; Longaker MT; Jensen RT
    JAMA Netw Open; 2020 Nov; 3(11):e2024318. PubMed ID: 33146734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Outcomes of Surgical Management of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases.
    Partelli S; Inama M; Rinke A; Begum N; Valente R; Fendrich V; Tamburrino D; Keck T; Caplin ME; Bartsch D; Thirlwell C; Fusai G; Falconi M
    Neuroendocrinology; 2015; 102(1-2):68-76. PubMed ID: 26043944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic fistulae after pancreatic resections for neuroendocrine tumours compared with resections for other lesions.
    Atema JJ; Jilesen AP; Busch OR; van Gulik TM; Gouma DJ; Nieveen van Dijkum EJ
    HPB (Oxford); 2015 Jan; 17(1):38-45. PubMed ID: 25041879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail. A propensity score survival evaluation.
    Bertani E; Fazio N; Radice D; Zardini C; Spinoglio G; Chiappa A; Ribero D; Biffi R; Partelli S; Falconi M
    Eur J Surg Oncol; 2017 Feb; 43(2):372-379. PubMed ID: 27742480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.
    Parekh JR; Wang SC; Bergsland EK; Venook AP; Warren RS; Kim GE; Nakakura EK
    Pancreas; 2012 Aug; 41(6):840-4. PubMed ID: 22781907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours.
    Yao J; Gan G; Farlow D; Laurence JM; Hollands M; Richardson A; Pleass HC; Lam VW
    ANZ J Surg; 2012 Mar; 82(3):140-4. PubMed ID: 22510123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of laparoscopic surgery for pancreatic neuroendocrine tumors.
    Haugvik SP; Marangos IP; Røsok BI; Pomianowska E; Gladhaug IP; Mathisen O; Edwin B
    World J Surg; 2013 Mar; 37(3):582-90. PubMed ID: 23263686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors in 151 patients with surgically resected non-functioning pancreatic neuroendocrine tumours.
    Song KB; Kim SC; Kim JH; Hong SM; Park KM; Hwang DW; Lee JH; Lee YJ
    ANZ J Surg; 2016 Jul; 86(7-8):563-7. PubMed ID: 25040037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic neuroendocrine tumor: A multivariate analysis of factors influencing survival.
    Birnbaum DJ; Turrini O; Ewald J; Barbier L; Autret A; Hardwigsen J; Brunet C; Moutardier V; Le Treut YP; Delpero JR
    Eur J Surg Oncol; 2014 Nov; 40(11):1564-71. PubMed ID: 25086992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients.
    Bilimoria KY; Talamonti MS; Tomlinson JS; Stewart AK; Winchester DP; Ko CY; Bentrem DJ
    Ann Surg; 2008 Mar; 247(3):490-500. PubMed ID: 18376195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of recurrence after surgery based on preoperative MRI features in patients with pancreatic neuroendocrine tumors.
    Han S; Kim JH; Yoo J; Jang S
    Eur Radiol; 2022 Apr; 32(4):2506-2517. PubMed ID: 34647178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of surgery for pancreatic neuroendocrine neoplasms.
    Fischer L; Bergmann F; Schimmack S; Hinz U; Prieß S; Müller-Stich BP; Werner J; Hackert T; Büchler MW
    Br J Surg; 2014 Oct; 101(11):1405-12. PubMed ID: 25132004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Grade 3 Pancreatic Neuroendocrine Tumors on MDCT: Establishing a Diagnostic Model and Comparing Survival Against Pancreatic Ductal Adenocarcinoma.
    Chen HY; Zhang XY; Deng XY; Ge YL; Tang YQ; Cui H; Yang B; Pan Y; Shi D; Yu RS
    AJR Am J Roentgenol; 2020 Aug; 215(2):390-397. PubMed ID: 32432906
    [No Abstract]   [Full Text] [Related]  

  • 20. Operative resection in early stage pancreatic neuroendocrine tumors in the United States: Are we over- or undertreating patients?
    Chivukula SV; Tierney JF; Hertl M; Poirier J; Keutgen XM
    Surgery; 2020 Jan; 167(1):180-186. PubMed ID: 31537303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.